In a continued show of financial robustness, Johnson & Johnson (NYSE:JNJ) has declared a 4.2% increase in its quarterly dividend, raising it from $1.19 per share to $1.24 per share. This adjustment marks the 62nd consecutive year the healthcare giant has increased its dividend, underscoring a long-standing commitment to delivering shareholder value. The new dividend rate elevates the annual payout to $4.96 per share, up from the previous $4.76 per share. Johnson & Johnson has scheduled the next quarterly dividend payout for June 4, 2024, with May 21, 2024, set as the record date for shareholders eligible to receive the dividend. Additionally, the ex-dividend date is announced as May 20, 2024.

Johnson & Johnson (NYSE:JNJ) reported lower-than-expected quarterly revenue as sales from its leading psoriasis treatment, Stelara, underperformed amidst looming market competition. The pharmaceutical giant saw its shares drop nearly 2% in premarket trading due to flat sales of Stelara, which amounted to $2.45 billion for the first quarter, falling short of the projected $2.6 billion. Despite the setback with Stelara, whose key patent expired last year, J&J has managed to delay the entry of biosimilar competitors in the U.S. until 2025. This strategic move is expected to bolster the drug’s contributions to J&J’s revenue through 2024 and 2025. On a brighter note, J&J’s blood cancer therapy Darzalex performed well, with sales increasing by 19% to $2.69 billion, aligning close

Morgan Stanley (NYSE:MS) has announced its financial outcomes for the first quarter of 2024, demonstrating robust growth with net revenues reaching $15.1 billion, up from $14.5 billion in the corresponding quarter last year. The firm's profitability also saw an uplift, with net income hitting $3.4 billion, or $2.02 per diluted share, an increase from the previous year's $3 billion, or $1.70 per diluted share. CEO Ted Pick praised the firm's performance, stating, "In the first quarter of 2024, Morgan Stanley generated net revenues of $15 billion and earnings of $2.02 per share for a 20% return on tangible equity." He highlighted the firm's achievement of $7 trillion in client assets across Wealth and Investment Management, backed by strong net new asset growth, as well as noting the strengt

AT&T (NYSE:T) has released its financial results for the first quarter of 2024, maintaining a steady performance with revenues holding at $30 billion, mirroring figures from the previous year. The Dallas-based telecommunications leader announced a diluted earnings per share (EPS) of $0.47, with an adjusted EPS of $0.55. The company also reported an operating income of $5.8 billion, an adjusted figure of $6 billion, and a net income of $3.8 billion. Additionally, the adjusted EBITDA stood at $11 billion. A notable financial highlight was the significant increase in cash from operating activities, which climbed by $0.9 billion to $7.5 billion. Free cash flow also saw a substantial rise, surging by $2.1 billion to reach $3.1 billion. AT&T's CEO, John Stankey, commented on the quarterl

Constellation Brands (NYSE:STZ) experienced a rise in its share value on Thursday following the release of its fourth-quarter earnings, which exceeded analyst forecasts. The company announced a revenue of $2.14 billion, topping predictions of $2.1 billion. Additionally, Constellation Brands reported adjusted earnings of $2.26 per share, outpacing the anticipated $2.10 per share. The company's beer division was highlighted as a key driver of this quarter's success, posting an impressive 11% increase in sales compared to the same period last year. In contrast, the wine and spirits segment didn't perform as well, showing a 6% drop in sales. Despite this dip, the robust performance of the beer business helped bolster the overall quarterly results for Constellation Brands.

Establishment Labs Holdings (NASDAQ:ESTA) has announced a pivotal development in its quest for U.S. market approval of its Motiva Implants. According to a recent filing with the Securities and Exchange Commission (SEC), the U.S. Food and Drug Administration (FDA) has slated a pre-approval inspection of the company's manufacturing facilities for the second quarter of 2024. This scheduled inspection marks a crucial milestone in Establishment Labs' regulatory journey, potentially paving the way for the approval of Motiva Implants in the United States. Read More #UnitedStates #News #Nasdaq #Food #SEC

Full story: https://grafa.com/news/lilium--nasdaq-lilm--triumphs-with-nasdaq-compliance-victory-222941 Lilium (NASDAQ:LILM) has successfully regained compliance with Nasdaq's minimum bid price requirement, as per a recent SEC filing. The company received a notice from Nasdaq Stock Market on May 15, 2024, confirming that it had met the necessary condition of maintaining a closing bid price of at least $1 per share for a minimum of 10 consecutive trading days. This development comes after Lilium was previously notified of its non-compliance on February 22, 2024, due to its share

Adidas stock price soared more than 7% on Wednesday, reaching a two-year high, after the sportswear manufacturer announced impressive quarterly results and upgraded its 2024 financial forecast. The spike in shares came as the German company revealed it had exceeded analysts' expectations in its recent earnings report on Tuesday. Adidas cited robust sales momentum in its retro "terrace" footwear lines, including popular models like the Samba, Gazelle, and Campus, as key growth drivers. This resurgence in retro styles, along with gains in performance sportswear, contributed significantly to the positive results. Wedbush analysts have noted that these segments are seeing particularly strong demand, which has helped bolster Adidas's market position. Meanwhile, Stifel's Cedric Lecasble emphasiz

Amplia Therapeutics launched a fully underwritten entitlement offer on a 2-for-5 basis to raise approximately $4.3 million. Priced at 5.5 cents per new share, this entails a 35.3% discount to the previous traded price. The funds will fuel crucial development initiatives, such as the Phase 2a ACCENT trial, the production of narmafotinib, and an investigator-initiated trial in ovarian cancer. The proceeds will also support ongoing trials and product development, with interim ACCENT trial results expected in the third quarter. Claim Now

Lincoln Minerals announced a substantial increase in its mineral resource estimate for the Kookaburra Graphite Project on the Eyre Peninsula. Total resources have surged 114% since September 2023, reaching 12.8Mt at 7.6% TGC, equating to about 973,000 tonnes of graphite. The upgrade will support an updated pre-feasibility study for a 60-100ktpa graphite concentrate project. Expansion of the high-grade core and the flat-lying orebody at the Kookaburra Gully extension is expected to enhance the feasibility study's economics. Lincoln Minerals plans additional drilling in 2024 and aims to leverage recent graphite export restrictions in China to meet growing demand. Claim

Negotiations between Salesforce (NYSE:CRM) and Informatica (NYSE:INFA) concerning a potential takeover have reached a standstill due to disagreements over the purchase price, a source close to the matter revealed. The talks, which could have resulted in one of Salesforce's largest acquisitions, have not seen progress as both companies failed to reach a consensus on the valuation.  This development marks a significant pause in what would have been a major expansion for Salesforce, following its historic purchases such as the $27 billion acquisition of Slack Technologies in 2021 and the $15 billion takeover of Tableau Software in 2019. Both Salesforce and Informatica have opted not to comment on the matter. 

Full story: https://grafa.com/news/warriedar-resources--asx-wa8--strikes-gold-at-ricciardo-deposit-in-western-australia-221268 Warriedar Resources announced gold findings at the Ricciardo deposit in Western Australia's Murchison region. Assay results from its latest drilling campaign reveal gold intervals, including 4m at 14.49 g/t gold, 12m at 1.91 g/t gold, and 7m at 1.17 g/t gold. The results expand the known high-grade shoot beneath the Ardmore pit and demonstrate additional mineralisation beyond the current model. The Ricciardo deposit, situated in

General Electric (NYSE:GE) officially completed its historic breakup into three independent companies today, marking a significant shift for the once-dominant industrial conglomerate. The move signifies the culmination of efforts by CEO Larry Culp to revitalize the company after years of struggle. GE's aerospace and energy divisions will begin trading as separate entities on the New York Stock Exchange, following the spin-off of its healthcare business. This finalizes Culp's strategic plan, announced in late 2021, a decision that eluded previous leadership as GE expanded into diverse sectors. GE's immense financial clout was evident when its finance arm was deemed "too big to fail" during the 2008 financial crisis. However, the company faced continuous challenges, culminating in its remova

Actinogen Medical completed patient enrollment for its XanaCIDD Phase 2a trial with 167 participants. The trial assesses Xanamem's efficacy in treating cognitive impairment in major depressive disorder patients by reducing brain cortisol levels without affecting normal stress response. Results are due in the early third quarter, focusing on improving cognitive functions beyond traditional antidepressants. Claim Now